Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis

Nephrology Dialysis Transplantation

Volumn 22, Issue 7, 2007, Pages 2052-2055

  Inoue, Hitoshi ^a   Nonomura, Norio ^a   Kojima, Yasuyuki ^b   Shiba, Masahiro ^a   Oka, Daizo ^a   Arai, Yasuyuki ^a   Nakayama, Masashi ^a   Takayama, Hitoshi ^a   Nishimura, Kazuo ^a   Mori, Hiroshi ^c   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Inoue Hospital   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Acquired cystic disease of the kidney; Dialysis; End stage renal disease; Renal cell carcinoma; von Hippel Lindau

Indexed keywords

DNA; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DNA EXTRACTION; DNA SEQUENCE; FRAMESHIFT MUTATION; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY FAILURE; LASER CAPTURE MICRODISSECTION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION;

ADENINE; AGED; BASE SEQUENCE; CARCINOMA; CARCINOMA, RENAL CELL; GENE DELETION; GUANINE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MIDDLE AGED; MUTATION; RENAL DIALYSIS; TIME FACTORS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34547839641     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm184     Document Type: Article

References (25)

1. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004
2. Committee on Static Survey, Japanese Society for Dialysis Therapy. An overview of dialysis treatment in Japan (in Japanese). Jpn J Dial Therapy 2005; 38: 1-16
3. Hughson MD, Henningar GR, MacManus JF. Atypical cysts, acquired renal cystic disease and renal cell tumors in end stage dialysis kidneys. Lab Invest 1980; 42: 475-480
4. Matson MA, Cohen EP. Acquired cystic kidney disease: Occurrence, prevalence and renal cancers. Medicine 1990; 69: 217-226
5. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 354: 93-99
6. Ishikawa I. Present status of renal cell carcinoma in dialysis patients: questionnaire based survey in 2002 (in Japanese). Jpn J Dial Therapy 2004; 37: 1605-1615
7. Choyke PL. Acquired cystic kidney disease. Eur Radiol 2000; 10: 1116-1221
8. Truong LD, Choi YJ, Shen SS, Ayala G, Amato R, Krishnan B. Renal cystic neoplasms and renal neoplasms associated with cystic renal diseases: pathogenetic and molecular links. Adv Anat Pathol 2003; 10: 135-159
9. Ishikawa I. Renal cell carcinomas in patients on long-term hemodialysis. Contrib Nephrol 1999; 128: 28-44
10. Cheuk W, Lo ES, Chan AK, Chan JK. Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations. Hum Pathol 2002; 33: 761-765
11. General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma. Japanese Urological Association, The Japanese Society of Pathology, Japan Radiological Society, eds. 3rd edn, Kanehara, Tokyo: 1999
12. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90
13. Latif F, Tory K; Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320
14. Shuin T, Kondo K, Tongue S et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994; 54: 2852-2855
15. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1: 822-826
16. Lonser RR, Glenn GM, Walther M et al. Von Hippel-Lindau disease. Lancet 2003; 361: 2059-2067
17. Bisceglia M, Galliani CA, Senger C, Stallone C, Sessa A. Renal cystic diseases: A review. Adv Anat Pathol 2006; 13: 26-56
18. Yoshida M, Ashida S, Kondo K et al. Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: An extended study of 77 families. Jpn J Cancer Res 2000; 91: 204-212
19. Gallou C, Joly D, Mejean A et al. Mutations of the VHL gene in sporadicrenal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999; 13: 464-475
20. Brauch H, Weirich G, Brieger J et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60: 1942-1948
21. Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002; 34: 58-68
22. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004; 10: 6290s-6295s
23. Schmidt L, Duh FM, Chen F et al. Germ-line and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73
24. Schmidt L, Junker K, Nakaigawa N et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343-2350
25. Yoshida M, Yao M, Ishikawa I et al. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. Genes Chromosomes Cancer 2002; 35: 359-364